📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

Pfizer gains as CEO said to meet activist Starboard

Published 10/09/2024, 12:52 PM
© Reuters
PFE
-

Investing.com -- Pfizer Inc. (NYSE:PFE) shares rose more than 3% on Wednesday following reports that CEO Albert Bourla is scheduled to meet with executives from activist hedge fund Starboard Value next week. 

The news reported by the Financial Times comes after a recent report from Reuters that said Starboard had taken a stake of approximately $1 billion in the pharmaceutical giant and is pushing for changes aimed at revitalizing the company's performance. 

According to the Financial Times, the meeting, which includes Pfizer's lead independent director Shantanu Narayen, who also serves as CEO of Adobe Systems (NASDAQ:ADBE), will involve discussions with Starboard’s chief executive Jeff Smith and Patrick Sullivan, head of its healthcare investments.

The discussions are said to signal an effort to address concerns raised by Starboard regarding Pfizer's recent struggles to regain momentum following its pandemic-related highs.

Since taking the helm in 2019, Bourla has faced challenges as Pfizer's revenues have decreased, particularly due to declining sales from COVID-19 products. 

Despite spending approximately $70 billion on acquisitions since 2020, including the notable $43 billion buyout of Seagen, Pfizer has yet to find a product that can effectively compensate for lost revenue from its COVID vaccine and treatment pill.

It was also reported that Pfizer's recent product launches have fallen short of expectations, including a weaker-than-anticipated rollout of its respiratory syncytial virus (RSV) vaccine and disappointing clinical data from an obesity pill under development. 

While the specifics of Starboard's recommendations remain unclear, their involvement suggests a push for strategic changes at Pfizer.

In a recent note to clients, Truist updated its models for Pfizer ahead of its earnings release, adjusting revenues primarily based on script tracking data and seasonality with Pfizer's vaccine portfolio. 

“We now model 3Q24E total revenue of $15.0B vs $16.2B prior and 3Q24 adj. EPS of $0.48 vs. $0.50 prior,” said the firm

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.